Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers Clear all
Completed Phase 1 Interventional

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

NCT03590054
View directory record Official record
Conditions
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Abexinostat, Pembrolizumab
Drug · Biological
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

NCT01868022
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3052230, paclitaxel, carboplatin, docetaxel, pemetrexed, cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

NCT02955251
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-428, Nivolumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

NCT04881045
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Suspended No phase listed Observational

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

NCT03987555
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Malignant Uterine Neoplasm, Vulvar Cancer, Invasive Breast Cancer, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vulvar Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vulva Squamous Cell Carcinoma
Interventions
Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

NCT05651022
View directory record Official record
Conditions
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
Interventions
Decoy20, Tislelizumab
Drug
Lead sponsor
Indaptus Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

NCT04977453
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
Interventions
GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
New York, New York • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337
View directory record Official record
Conditions
Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
Interventions
NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jul 24, 2026, 4:18 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328
View directory record Official record
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 24, 2026, 4:18 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor
Interventions
PLN-101095, Pembrolizumab
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 24, 2026, 4:18 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

NCT05462873
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Interventions
QEQ278
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

NCT04504669
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
Interventions
AZD8701, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 101 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Jul 24, 2026, 4:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

NCT01976741
View directory record Official record
Conditions
Neoplasms
Interventions
Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

NCT03829436
View directory record Official record
Conditions
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions
Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Drug
Lead sponsor
Tempest Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 24, 2026, 4:18 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
MCLA-129, Osimertinib, Chemotherapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

NCT03245736
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
Interventions
Tisotumab Vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 24, 2026, 4:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 24, 2026, 4:18 AM EDT
Active, not recruiting Phase 1 Interventional

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05973487
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
Biological
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 24, 2026, 4:18 AM EDT
Terminated Phase 1 Interventional

Safety Study of SEA-CD40 in Cancer Patients

NCT02376699
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Hodgkin Disease, Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Melanoma, Neoplasm Metastasis, Neoplasms, Head and Neck, Neoplasms, Squamous Cell, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, Squamous Cell Cancer, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Neoplasm, Lymphoma, Non-Hodgkin, Pancreatic Adenocarcinoma
Interventions
Intravenous (IV) SEA-CD40, Pembrolizumab, Subcutaneous (SC) SEA-CD40, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Jul 24, 2026, 4:18 AM EDT
Completed Phase 1 Interventional

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

NCT03752398
View directory record Official record
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 24, 2026, 4:18 AM EDT